The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Liraglutide and Renal Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively). CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The LEADER and REWIND trials also report a greater than 20% reduction in the risk of developing new macroalbuminuria, along with favourable trends in other clinically relevant adverse renal outcomes. 26,27”
The cited source says what the claim attributes to it.
In the citing paper
“Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have also been shown to improve kidney outcomes (95-100).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs have also been shown to improve kidney outcomes (104-109).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [106]
In the citing paper
“However, the composite kidney outcomes in these trials were evaluated as secondary outcomes, and the reported effects were largely driven by a lower risk of new-onset macroalbuminuria. 23-25”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [24]
In the citing paper
“Treatment with these drugs is in fact associated with a reduced decline in the estimated glomerular filtration rate (eGFR), as well as with a reduction in urinary albumin excretion and in the incidence rate of de novo albuminuria [28,29].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [28]
In the citing paper
“However, these benefits were driven by a lower risk of persistent macroalbuminuria [6,10,13].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationStevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952
Flagged first, then by citations
1 of the 32 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Trillini, M., Jenssen, T. G., Martin, W. P., & Morales, E. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf008 · Cited by 3
Szostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.361 · Cited by 3
Alam, A., Imran, M., Rehman, Z. U., Sahoo, B. M., & Mahapatra, M. K. (2025) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-025-01108-5 · Cited by 3
Soriano, L. C., Moreno-Lostao, A., Calonge, M., Rivas, A., Pulido, J., Colchero, M. C., Artola, S., Serrano, R., Franch‐Nadal, J., & Regidor, E. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-106069 · Cited by 3
Florescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 3
Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights
Dayel, F. F. B. (2025) · Healthcare · doi:10.3390/healthcare13222922 · Cited by 3
Matheou, A., Zavlis, O., White, S., McDonnell, T., Warner‐Levy, A., Warner-Levy, J. J., Wilkins, L., Habte‐Asres, H. H., Lay, A. C., Shalamanova, L., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70193 · Cited by 3
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062757 · Cited by 3
GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Ramadurgum, P., Sharma, K. M., Pinon, A., Kattamuri, L. P. V., & Botros, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02356-6 · Cited by 3
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Monnier, L., Halimi, S., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30007-5 · Cited by 3
Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?
Bellary, S., Tahrani, A. A., & Barnett, A. H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30301-6 · Cited by 3
Cardiovascular Outcomes Trials of Incretin-Based Therapies
Thethi, T. K., Bilal, A., & Pratley, R. E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0072 · Cited by 3
Advances in Imaging Techniques for Assessing Myocardial Microcirculation in People with Diabetes
Hansen, T. W., & Ripa, R. S. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01710-1 · Cited by 3
Updates in chronic kidney disease management: A systematic review
Ammar, A., Edwin, S. B., Whitney, R., Lipari, M., & Giuliano, C. A. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70014 · Cited by 3
Zhang, L., Li, X., Zhang, J., Wang, X., & Fu, Y. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70118 · Cited by 3
Recent Updates on Diabetic Nephropathy
Kee, Y. K., & Han, S. H. (2017) · Journal of Korean Diabetes · doi:10.4093/jkd.2017.18.4.214 · Cited by 3
Key Updates in Cardio-Nephrology from 2018: Springboard to a Bright Future
Rangaswami, J., Soman, S. S., & McCullough, P. A. (2019) · Cardiorenal Medicine · doi:10.1159/000498916 · Cited by 3
Afectación renal en la diabetes mellitus
Barrio, F. M., Torres, C. C., & Esparragoza, J. K. P. (2019) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2019.05.031 · Cited by 3
Glucagon-like Peptide-1 Receptor Agonists: Limitless Potential
Demidova, T. Y., & Kozhevnikov, A. A. (2020) · Doctor Ru · doi:10.31550/1727-2378-2020-19-2-6-12 · Cited by 3
Series: Cardiovascular outcome trials for diabetes drugs Lixisenatide and ELIXA
Fisher, M. (2020) · British Journal of Diabetes · doi:10.15277/bjd.2020.241 · Cited by 3
Huang, C., Chen, C., Yy, H., & Hsu, B. (2020) · Journal of Postgraduate Medicine · doi:10.4103/jpgm.jpgm_680_19 · Cited by 3
Heterogeneity in renal end points of cardiovascular outcomes trials in Type 2 diabetes
Balijepalli, C., Yan, K., Zoratti, M. J., Franklin, M., & Druyts, E. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0137 · Cited by 3
Doggrell, S. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1904892 · Cited by 3
Morales, J., & Assumpcao‐Morales, M. (2019) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2019.12.00450 · Cited by 3
Antidiabetic Medication-Induced Acute Interstitial Nephritis: Case Report and Literature Search
Chaudhury, N., Liarakos, A. L., Gopalakrishnan, K., Ayub, W., Murthy, N., & Rao, R. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.321 · Cited by 3
Varadhan, L., Saravanan, P., Ali, S. N., Hanif, W., & Patel, V. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-021-01105-7 · Cited by 3
Zhang, Q., Wang, Z., Xu, H., Li, Q., An, R., & Zhang, Y. (2022) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v20i8.17 · Cited by 3
Deng, Y., Ghamsari, F., Lu, A., Yu, J., Zhao, L., & Kho, A. (2022) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2022.100309 · Cited by 3
Toapanta, N., Sánchez, E., Guirao, C., León-Román, J. C., Ramos-Terrades, N., Vergara, A., Azancot, M. A., Agraz, I., Bermejo, S., Montiel, E., et al. (2023) · Nefrología · doi:10.1016/j.nefro.2023.01.008 · Cited by 3
The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
Fang, H., Niu, B., & Chen, Q. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230416153301 · Cited by 3
[Non-Classical Clinical Types and Pathological Changes of Diabetic Kidney Disease: A Review].
Fang, C., Sun, L., Liu, Y., Xiao, L., & Sun, L. (2023) · 四川大学学报：医学版 · doi:10.12182/20231160102 · Cited by 3
The expert consensus on care and education for patients with diabetic kidney disease in Taiwan
Hsu, C., Yeh, C.-Y., Yen, T.-Y., Chen, C., Chen, J.-F., Chu, C., Huang, C., Lin, C., Lin, S., Liu, F.-H., et al. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.02.003 · Cited by 3
Jang, C.-W., Yu, T. Y., Jeong, J. W., Ha, S. E., Singh, R., Lee, M. Y., & Ro, S. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14030280 · Cited by 3
A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease
AlHabeeb, W., Kinsara, A. J., Bakhsh, A., Tash, A. A., Alshammary, A., Almasood, A. S., Alghalayini, K. W., Arafah, M., Hamdy, O., Alsifri, S. N., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1391 · Cited by 3
Müller‐Wieland, D., Brandts, J., Verket, M., Marx, N., & Schütt, K. S. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_537 · Cited by 3
The impact of glucose-lowering medications on cardiovascular disease
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2017) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000139 · Cited by 3
Maddaloni, E., & Buzzetti, R. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3012 · Cited by 3
Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder
Rossing, P. R., Frimodt‐Møller, M., & Persson, F. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.11.005 · Cited by 3
Rossing, P. R., Persson, F., & Frimodt‐Møller, M. (2019) · Kidney International · doi:10.1016/j.kint.2019.03.002 · Cited by 3
Nouraei, H., Leiter, L. A., Tan, M., Langer, A., Teoh, H., CHENG, A. Y. Y., Wald, R., Connelly, K. A., Goodman, S. G., & Yan, A. T.-K. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.02.003 · Cited by 3
Alsaidan, M., Alkhenizan, A. H., Amber, S. T., Alsoghayer, S. A., Alfakhri, L., & Abudaia, J. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s301933 · Cited by 3
Diabetic Chronic Kidney Disease in Type 2 Diabetes Mellitus (Albuminuric/Non-albuminuric)
Roumeliotis, S. K., Mallamaci, F., & Zoccali, C. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_16 · Cited by 3
Packer, M. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.10.020 · Cited by 3
Borg, R., & Persson, F. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.02 · Cited by 3
Matthews, D. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14014 · Cited by 3
Efficacy and Safety of Vildagliptin for Type 2 Diabetes in Patients With Diabetic Kidney Disease
Mima, A., NAKAMOTO, T., Saito, Y., Matsumoto, K., & Lee, S. (2024) · In Vivo · doi:10.21873/invivo.13635 · Cited by 2
Koman, A. M., Przygodzka, S., Gadżała, K., Janik, I., Pliszka, M., Palacz, K. A., Kułak, K. B., Sztybór, I., Kuśmierska, M., & Chamera-Cyrek, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52659 · Cited by 2
Cheng, W.-J., Yeh, T.-Y., Hsieh, C., Chuang, H., Chao, F.-C., Liou, J.-P., & Hsieh, C. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106909 · Cited by 2
Abdel-Razek, N. S., Nassar, N. N., Sayed, R. H., El-Sahar, A. E., & Abdallah, D. M. (2025) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2025.127755 · Cited by 2
Shetty, S., Karunakara, M. B., Kristipati, R. R., Kalthur, G., & Kumari, S. (2025) · F1000Research · doi:10.12688/f1000research.167998.1 · Cited by 2
Update on clinical heart failure trials
Hoevelmann, J., Tokcan, M., Kulenthiran, S., Abdin, A., Viljoen, C. A., & Böhm, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02784-4 · Cited by 2
Zou, Q., Li, L., Ye, H., Chen, Q., Li, B., & Wei, L. (2025) · The FASEB Journal · doi:10.1096/fj.202502041rrr · Cited by 2
Therapeutic Considerations in Preventing Chronic Kidney Disease
Nicholas, S. B., Nobakht, N., & Alicic, R. Z. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-013325 · Cited by 2
Non-diabetic Kidney Disease in Type 2 Diabetes: From Kidney Biopsy to Precision Medicine
Sreedharan, S., Mohandas, M. K., Vismaya, K. B., & Raju, N. (2026) · Cureus · doi:10.7759/cureus.100716 · Cited by 2
Linagliptin loaded chitosan nanoparticles for the efficient therapy of renal fibrosis
Wu, Z., He, Y., Deng, H., Tan, Y., Gao, W., Yin, J., Zeng, Z., Sun, J., Zhang, L., Li, Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1773015 · Cited by 2
Cao, J., Dun, Z., Tian, D., Qiao, Z., & Wang, Y. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s580866 · Cited by 2
Kim, Y. (2026) · Cells · doi:10.3390/cells15070595 · Cited by 2
Koperdowska, J. M., & Broen, J. A. (2026) · Medical Research Journal · doi:10.5603/mrj.111322 · Cited by 2
Habas, E., Rayani, A., Habas, A., Alarbi, K., Habas, A., Baghi, M., Habas, E., Errayes, E., Hamad, A., & Elzouki, A. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2688578 · Cited by 2
Chai, X.-J., Wei, G., Chen, W., Min, D.-Y., Wang, Y., & Guan, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1801502 · Cited by 2
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
Patoulias, D., Papadopoulos, C. E., & Doumas, M. N. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.5171 · Cited by 2
SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
Stanton, R. C. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.03.003 · Cited by 2
Soejima, H., Ogawa, H., Morimoto, T., Okada, S., Matsumoto, C., Nakayama, M., Masuda, I., Jinnouchi, H., Waki, M., Saito, Y., et al. (2022) · Heart and Vessels · doi:10.1007/s00380-022-02085-0 · Cited by 2
Diallo, A., Carlos‐Bolumbu, M., Renard, É., & Galtier, F. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14859 · Cited by 2
Semaglutida en enfermedad renal diabética: Experiencia en dos programas de salud renal en Colombia
Daza-Arnedo, R., Rico-Fontalvo, J. E., Raad-Sarabia, M., Clason, E. C. R., Bohórquez-Rivero, J., Montejo-Hernández, J. D., Cabrales, J., Escobar-Pacheco, C., Pérez, T. A. A., Henao-Ramirez, C., et al. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.9.3.776 · Cited by 2
Li, X., Sun, T., Du, X., Xie, X., & Shi, L. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2021-0533 · Cited by 2
Efeito dos Agonistas GLP-1 no Controle do Diabetes Mellitus Tipo 2
Barroso, A. C., Avelar, G. T., Minucci, G. R., & Almeida, V. A. R. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n8p5029-5035 · Cited by 2
Bai, S., Lin, C., Cai, X., Wu, H., Jiao, R., Hu, S., Lv, F., Yang, W., & Ji, L. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12646 · Cited by 2
Chen, S., He, M., Qin, Y., Tian, J., Liang, Z., Li, Y., Wang, P., Zhang, Y., Zhou, C. L., & Xiao, J. (2024) · Medicine · doi:10.1097/md.0000000000040438 · Cited by 2
GLP-1 Receptor Agonists for CKD: Remaining Issues or Mission Complete?
Kosjerina, V., & Rossing, P. R. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.001 · Cited by 2
Shaping the future of youth-onset type 2 diabetes: a call to action
SHAH, A. S., Kelsey, M. M., Wolf, R. M., & Nadeau, K. J. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.003 · Cited by 2
Liu, W.-H., Liu, C., Xue, Y., Sun, X., Chen, X., & Chen, L. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1529919 · Cited by 2
Hung, T., Lin, T., Liou, Y., Lin, T., Hsu, Y., Lin, L., & Wang, M. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20112 · Cited by 2
Blonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
Medications for the Treatment of Type II Diabetes
Name, M. A. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55138-0.00012-7 · Cited by 2
Martínez‐Castelao, A., Soler, M. J., Navarro‐González, J. F., & Górriz, J. L. (2019) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2018.05.004 · Cited by 2
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Niezen, S., del Castillo, H. D., Castaner, L. A. M., & Fornoni, A. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.72 · Cited by 2
Deerochanawong, C., Kosachunhanun, N., Gadekar, A. V., Chotikanokrat, P., & Permsuwan, U. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s201951 · Cited by 2
Renoprotection in diabetic kidney disease
van Baar, M. J. B., & van Raalte, D. H. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000559 · Cited by 2
Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER
Fisher, M. (2020) · British Journal of Diabetes · doi:10.15277/bjd.2020.267 · Cited by 2
Sanajou, D., Bahrambeigi, S., & Aslani, S. (2021) · PubMed · doi:10.22038/ijbms.2021.55565.12422 · Cited by 2
Lam, A. Y. R., Zheng, H. F., Teo, K. K., Xin, X. H., Tan, C. S., Kovalik, J., Ghosh, S., & Tan, H. C. (2021) · Singapore Medical Journal · doi:10.11622/smedj.2021179 · Cited by 2
Silva‐Nunes, J., Nascimento, E., Louro, J., Dores, J. M., Laginha, T., Gonçalves-Ferreira, A., Alves, M., Souto, S. B., Cunha, N. C., Pina, E., et al. (2022) · Metabolites · doi:10.3390/metabo12111121 · Cited by 2
Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
Shin, J., Kim, R., & Kim, H. (2023) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2023.5.e7 · Cited by 2
Kobayashi, K., Toyoda, M., Hatori, N., Tsukamoto, S., Kimura, M., Sakai, H., Furuki, T., Chin, K., Kanaoka, T., Aoyama, T., et al. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000292 · Cited by 2
Dulaglutide slows kidney disease in type 2 diabetes
Oliva-Dámaso, N., Oliva-Dámaso, E., Payán, J., & Porrini, E. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32550-4 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00608-9 · Cited by 2
- Retracted
Koufakis, T., Popovic, D. S., Karakasis, P., Georgianos, P. I., & Patoulias, D. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2416584 · Cited by 2
Vashisht, R., Dhruva, S. S., Patel, A. R., Dahm, L., Morris, P., Gonzalez, D. M., Follett, R., Sirota, M., Singh, K., Han, C., et al. (2025) · SSRN Electronic Journal · doi:10.1101/2025.08.13.25333579 · Cited by 2
Zhao, C., Li, X., Ma, J., Zhu, Z., Li, H., Lou, F., Zhai, Y., Chen, H., Xiao, S., Peng, Q., et al. (2021) · All Life · doi:10.1080/26895293.2021.1917457 · Cited by 1
Diabetic Kidney Disease: State of the Art
Calvo, C. P. (2022) · Journal of Diabetes Research Review & Reports · doi:10.47363/jdrr/2022(4)156 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 1
Diabetic Kidney Disease: Increasing Hope with Transformative Therapies
Rosas, S. E., & Nasser, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-42045-0_4 · Cited by 1
Imai, D., Ushigome, E., Sakai, R., Kitagawa, N., Hamaguchi, M., Yamazaki, M., & Fukui, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14218 · Cited by 1
Dayel, A. F. B., Al-Rasheed, N. M., Alonazi, A. S., Alamin, M. A., Al-Mutairi, N. M., & Alateeq, R. A. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae127 · Cited by 1
Lozano, F. P., Marcos, A. R., Fernández, R. C., Rodrigo, A. B., Martínez‐Hervás, S., & Ampudia‐Blasco, F. J. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501574 · Cited by 1
Barber, T., Neumiller, J. J., Fravel, M. A., Page, R. L., II, & Tuttle, K. R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf045 · Cited by 1
Metadata
- Authors
- Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B.
- Affiliations
- Mount Sinai Hospital (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 839-848
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752707491
- Semantic Scholar
- e3932087f500b455476965939bdced15360eb028
- Cited by
- 1,253
- References
- 32
- Citations by year
- 2026: 99 · 2025: 116 · 2024: 121 · 2023: 131 · 2022: 134 · 2021: 161 · 2020: 180 · 2019: 139 · 2018: 152 · 2017: 20
- FWCI
- 106.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- ResearchOnline - JCU (James Cook University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Novo Nordisk
- National Institutes of Health (UL1TR001111)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- liraglutide, type 2 diabetes, renal outcomes, diabetic nephropathy, macroalbuminuria, end-stage renal disease, acute kidney injury, glucagon-like peptide-1 analogues, albuminuria, estimated glomerular filtration rate, cardiovascular risk, renal adverse effects, LEADER trial, cardiovascular outcomes, serum creatinine doubling, usual care
- MeSH terms
- Liraglutide, Aged, Albuminuria, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Kidney Failure, Chronic, Male, Middle Aged, Glucagon-Like Peptide 1, Intention to Treat Analysis, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
